Tevogen Bio (TVGN) Competitors $1.20 +0.03 (+2.56%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.25%) As of 08:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN vs. GYRE, OCS, REPL, COGT, DAWN, EOLS, AVDL, AVXL, PHVS, and CDMOShould you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Gyre Therapeutics (GYRE), Oculis (OCS), Replimune Group (REPL), Cogent Biosciences (COGT), Day One Biopharmaceuticals (DAWN), Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Anavex Life Sciences (AVXL), Pharvaris (PHVS), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry. Tevogen Bio vs. Gyre Therapeutics Oculis Replimune Group Cogent Biosciences Day One Biopharmaceuticals Evolus Avadel Pharmaceuticals Anavex Life Sciences Pharvaris Avid Bioservices Tevogen Bio (NASDAQ:TVGN) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings. Which has preferable valuation and earnings, TVGN or GYRE? Tevogen Bio has higher earnings, but lower revenue than Gyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTevogen BioN/AN/A-$70KN/AN/AGyre Therapeutics$105.76M8.05-$92.93M$0.05181.80 Does the media prefer TVGN or GYRE? In the previous week, Gyre Therapeutics had 3 more articles in the media than Tevogen Bio. MarketBeat recorded 8 mentions for Gyre Therapeutics and 5 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 0.47 beat Gyre Therapeutics' score of 0.31 indicating that Tevogen Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of TVGN or GYRE? 24.0% of Gyre Therapeutics shares are owned by institutional investors. 56.6% of Tevogen Bio shares are owned by insiders. Comparatively, 19.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend TVGN or GYRE? Tevogen Bio currently has a consensus price target of $7.10, indicating a potential upside of 491.67%. Given Tevogen Bio's higher probable upside, analysts clearly believe Tevogen Bio is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tevogen Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in TVGN or GYRE? Tevogen Bio received 2 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformTevogen BioOutperform Votes3100.00% Underperform VotesNo VotesGyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Which has more volatility and risk, TVGN or GYRE? Tevogen Bio has a beta of -1.07, meaning that its stock price is 207% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Is TVGN or GYRE more profitable? Tevogen Bio has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -84.57%. Gyre Therapeutics' return on equity of -118.43% beat Tevogen Bio's return on equity.Company Net Margins Return on Equity Return on Assets Tevogen BioN/A -396.07% 749.97% Gyre Therapeutics -84.57%-118.43%-71.97% SummaryTevogen Bio beats Gyre Therapeutics on 8 of the 13 factors compared between the two stocks. Remove Ads Get Tevogen Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVGN vs. The Competition Export to ExcelMetricTevogen BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$210.06M$3.04B$5.64B$8.06BDividend YieldN/A1.54%4.56%4.02%P/E RatioN/A29.2923.1319.03Price / SalesN/A436.17383.8993.17Price / CashN/A168.6838.1634.64Price / Book-1.093.956.944.33Net Income-$70,000.00-$71.95M$3.20B$247.06M7 Day Performance2.56%-4.63%-2.30%-0.52%1 Month Performance-4.00%-9.29%3.10%-3.73%1 Year Performance-65.42%-25.75%11.22%1.74% Tevogen Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVGNTevogen Bio3.2154 of 5 stars$1.20+2.6%$7.10+491.7%-65.4%$210.06MN/A0.003GYREGyre Therapeutics0.2041 of 5 stars$9.21-5.1%N/A-48.1%$862.17M$105.76M184.2040News CoverageHigh Trading VolumeOCSOculis1.9889 of 5 stars$19.61+0.2%$29.50+50.4%+62.9%$856.21M$980,000.00-10.162Short Interest ↑REPLReplimune Group3.8551 of 5 stars$11.05+2.1%$19.43+75.8%+26.7%$851.02MN/A-3.60210Positive NewsCOGTCogent Biosciences2.4137 of 5 stars$7.40+3.4%$14.43+95.0%+1.4%$842.49MN/A-2.9880Positive NewsDAWNDay One Biopharmaceuticals2.9913 of 5 stars$8.31+1.0%$34.57+316.0%-48.1%$842.26M$131.16M-8.0760Analyst ForecastEOLSEvolus3.9948 of 5 stars$13.00-0.2%$24.67+89.7%-12.6%$826.63M$266.27M-14.29170AVDLAvadel Pharmaceuticals3.3628 of 5 stars$8.53-0.5%$19.88+133.0%-51.8%$824.25M$169.12M-10.8070Positive NewsAVXLAnavex Life Sciences3.7863 of 5 stars$9.61-1.3%$44.00+357.9%+88.5%$817.47MN/A-17.4740Positive NewsPHVSPharvaris1.4403 of 5 stars$15.47+0.5%$40.50+161.8%-33.7%$808.93MN/A-5.5330Gap UpCDMOAvid Bioservices1.0299 of 5 stars$12.50+0.1%$12.25-2.0%+79.0%$799.18M$139.91M-5.23320High Trading Volume Remove Ads Related Companies and Tools Related Companies Gyre Therapeutics Competitors Oculis Competitors Replimune Group Competitors Cogent Biosciences Competitors Day One Biopharmaceuticals Competitors Evolus Competitors Avadel Pharmaceuticals Competitors Anavex Life Sciences Competitors Pharvaris Competitors Avid Bioservices Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVGN) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
